ClinicalTrials.gg
CompletedNCT04838964Updated Sep 9, 2026

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

A Phase 2 interventional study of MRG003 in Advanced or Metastatic Biliary Tract Cancer, sponsored by Lepu Biopharma Co., Ltd.. Completed at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Lepu Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 176 studies in Biliary Tract Neoplasms with a site in China — 93 open to participants now, 111 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.

Enrollment
153rd of 157
15 · median 62
Started
2021
with 10 others
Phase 2
94 of 176
52 open now
Registered
51st of 176
by date

Among the 176 studies in Biliary Tract Neoplasms with a site in China, this one is the 153rd largest by enrollment of the 157 interventional ones that give a count, is one of 11 that started in 2021, is one of 94 in phase 2, and was the 51st registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 199 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

93 of the 176 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Biliary Tract Neoplasms with a site in China, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 as single agent in EGFR-positive unresectable locally advanced or metastatic biliary tract cancer patients who have progressed during or relapsed after at least one prior standard therapy.

Read the detailed description

The study consists of two stages. In Phase IIa, approximately 25 subjects will be enrolled to evaluate the safety and preliminarily efficacy of MRG003. Based on the safety and efficacy data obtained from the Phase IIa, the study design of the second stage Phase IIb single-arm study either will be adjusted or the trial will be stopped. If the initial Phase IIa data support the continuation of the study, in the second stage, approximately an additional 55 subjects will be enrolled to further evaluate the efficacy and safety of MRG003.

03

Conditions studied

  • Advanced or Metastatic Biliary Tract Cancer

Keywords

  • MRG003
  • Antibody Drug Conjugate (ADC)
  • EGFR
  • Biliary Tract Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to sign the ICF and follow the requirements specified in the protocol.
  2. Aged 18 to 75 (including 18 and 75), both genders.
  3. Expected survival time ≥ 12 weeks.
  4. Patients with unresectable locally advanced or biliary tract cancer confirmed by histopathology.
  5. Failed in the prior one or more standard therapies.
  6. EGFR positive in the tumor specimens confirmed by central laboratory test.
  7. Archival or tumor specimens should be provided (primary or metastatic).
  8. Patients must have according to the (RECIST v1.1).
  9. performance score 0 or 1.
  10. Prior anti-tumor treatment-related AEs ( v5.0 Criteria) have recovered to ≤ Grade 1 (except alopecia, non- or asymptomatic laboratory abnormalities).
  11. No severe cardiac dysfunction with (LVEF) ≥ 50%.
  12. Organ function must meet the basic requirements.
  13. Coagulation function must meet the basic requirements.
  14. Patients of must take effective measures during the treatment and for 6 months after the last dose of treatment.

Exclusion criteria

Exclusion Criteria:

  1. History of to any component of MRG003.
  2. Received chemotherapy, radiotherapy, biologicals, immunotherapy, or other anti-tumor drugs within 4 weeks prior to the first dose.
  3. Presence of clinical manifestation of biliary obstruction.
  4. Patients with clinical symptoms such as pleural, abdominal or pericardial effusion requiring puncture drainage.
  5. Presence of central nervous system (CNS) and/or neoplastic meningitis.
  6. Any severe or uncontrolled systemic diseases.
  7. Patients with poorly controlled heart diseases.
  8. Evidence of active infections, including but not limited to , , or (HIV) infection.
  9. History of other primary .
  10. History of the following ophthalmologic abnormalities:severe dry eye syndrome; keratoconjunctivitis sicca; severe exposure keratitis; any other condition that may increase the risk of corneal epithelial damage.
  11. History of severe skin disease or chronic skin disease requiring oral or intravenous treatment.
  12. History of interstitial pneumonia, severe , severe pulmonary insufficiency, symptomatic bronchospasm, etc.
  13. Peripheral neuropathy greater than Grade 1.
  14. Patients with active disease or a history of autoimmune disease, who are using agents, or systemic hormone therapy and still receiving within 2 weeks prior to enrollment.
  15. History of cirrhosis (decompensated cirrhosis class B and C).
  16. Received anti-tumor vaccine treatment 4 weeks prior to the first dose or planning to participate in anti-tumor vaccine trials.
  17. Female patents with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate measures during the treatment and for 6 months after the last dose of study treatment.
  18. Other conditions inappropriate for participation in this clinical trial, at the discretion of the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    MRG003

    MRG003 will be administrated via IV infusion at 2.0 mg/kg on Day 1 of every 3 weeks (21-day cycle).

    Drug: MRG003

Interventions

  • DrugMRG003

    Administrated intravenously

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) by Independent Review Committee (IRC)

    ORR is defined as the percentage of patients with a complete response (CR) and partial response (PR) as assessed by Independent Review Committee (IRC) according to RECIST v1.1.

    Time frame: Baseline to study completion, up to 12 months

Secondary outcomes

  1. ORR by Investigator

    ORR is defined as the percentage of patients with a CR and PR as assessed by Investigator according to RECIST v1.1.

    Time frame: Baseline to study completion, up to 12 months

  2. Duration of Response (DoR)

    DOR is defined as the time from first documented objective response to the first onset of tumor progression or death of any cause.

    Time frame: Baseline to study completion, up to 12 months

  3. Time to Response (TTR)

    TTR is defined as the duration from the start of treatment to the first onset of CR or PR in tumor evaluation.

    Time frame: Baseline to study completion, up to 12 months

  4. Disease Control Rate (DCR)

    DCR is defined as the percentage of patients who achieve CR, PR, and stable disease (SD) after treatment.

    Time frame: Baseline to study completion, up to 12 months

  5. Progression Free Survival (PFS)

    PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.

    Time frame: Baseline to study completion, up to 12 months

  6. Overall Survival (OS)

    OS is defined as the duration from the start of treatment to death of any cause.

    Time frame: Baseline to study completion, up to 12 months

  7. Adverse Events (AEs)

    Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.

    Time frame: Baseline to 30 days after the last dose of study treatment

  8. Pharmacokinetics (PK) parameter of MRG003: concentration-time curve

    Concentration-time curve will be depicted based on pharmacokinetics concentration set (PKCS).

    Time frame: Baseline to 30 days after the last dose of study treatment

  9. Incidence of anti-drug antibody (ADA)

    The incidence of ADA analysis will be summarized for all patients who received at least one cycle study treatment.

    Time frame: Baseline to 30 days after the last dose of study treatment

07

Study locations

7 sites
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100000, China
  • Beijing Youan Hospital,Capital Medical University
    Beijing, Beijing Municipality 100007, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410031, China
  • Bethune First Hospital of Jilin University
    Changchun, Jilin 130061, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Oct 2022, 17 months.

Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 9, 2021
StartActual
May 18, 2021
Primary completionActual
Oct 20, 2022
CompletionActual
Oct 20, 2022
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04838964
Lead sponsor
Lepu Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Apr 9, 2021
Start date
May 18, 2021
Primary completion
Oct 20, 2022
Completion
Oct 20, 2022
Last update
Sep 9, 2026

Study contacts

Aiping Zhou, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Becotatug vedotin

Start the discussion